Stockreport

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study [Yahoo! Finance]

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF C virus infection that causes liver swelling and can lead to serious liver damage The study met its primary endpoints of safety and sustained virologic response at 12 [Read more]